DNA

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland

Ginkgo provides an update on its second quarter financial results and its continued efforts to scale Nebula, its Boston-based autonomous cloud lab

BOSTON, Mass – August 5, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the second quarter of 2026 that ended June 30, 2026. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.

Second Quarter 2026 Financial Results

•Second quarter 2026 Revenue of $20 million compared to $39 million in the comparable prior year period, a decrease of 48%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities.

•Second quarter 2026 GAAP net loss from continuing operations of ($57) million, compared to ($53) million in the comparable prior year period.

•Second quarter 2026 Adjusted EBITDA of ($36) million, down from ($25) million in the comparable prior year period.

•Cash, cash equivalents and marketable securities balance as of June 30, 2026 of $302 million.

"Autonomous labs are increasingly becoming necessary national infrastructure for American science," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "The White House and the National Science Foundation are now investing billions to move experimentation off the bench and into AI-enabled labs that scientists can run from anywhere, and Ginkgo is proud to be helping build that future—both with Nebula, already the world's largest autonomous lab, and by powering several of the new NSF cloud lab nodes with our automation. We're using that same infrastructure to bring high-value R&D back onshore to the U.S., and to help lead the transition from the manual lab bench to autonomous research infrastructure that runs 24/7 and plugs directly into the AI models transforming drug discovery."

Recent Business Highlights & Strategic Positioning

•Autonomous labs are becoming an imperative for American science.

◦The White House has called for the U.S. to "build autonomous laboratories that leverage robotics, edge AI, and real-time analysis to enable self-driving experimentation…which scientists can run and replicate from anywhere in the country," backed by $5 billion of investment through the Genesis Mission.

◦Caltech, Northwestern, and the University of Maryland have all commissioned autonomous labs to be built by Ginkgo under the NSF’s ~$400 million investment to establish a national network of AI-enabled "cloud labs".

◦MIT Media Lab awarded grant from the Massachusetts Life Sciences Center to build a Cloud Laboratory for Learning, supported by Ginkgo RACs.

◦Ginkgo has begun work on a $47 million, 97-instrument autonomous lab for the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory.

•Nebula, our autonomous lab, is the largest in the world—and it is scaling rapidly.

◦Nebula is in “ramp” mode, scaling rapidly as we onboard new protocols to the system weekly.

◦More than 100 robots can run experiments around the clock for our Cloud Lab, Datapoints, and Solutions businesses.

◦In Q3, we are increasing the total number of devices housed in Nebula’s RACs.

•Our pharma services continue to onshore American industry through innovation.

◦Ginkgo believes it is well positioned to provide core next-gen R&D infrastructure / services to U.S.-based biopharma companies.

◦Our new ADME-One service is cheaper than WuXi by 10X, with work done in Boston, and has signed on 17 customers in the first 6 weeks.

◦More expected soon: automated nano-scale chemistry on RACs, multistep synthesis, safety-seq, biochemical screens.

Full Year 2026 Outlook

•Ginkgo reaffirms expected total cash burn of ($150)-($125) million in 2026.

Conference Call Details

Ginkgo will host a videoconference today, Wednesday, August 5, beginning at 4:30 p.m. ET. The presentation will include an overview of the second quarter 2026, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:

+1 646 876 9923 (New York - ET)

+1 301 715 8592 (Washington DC - ET)

+1 305 224 1968 (Miami - ET)

+1 689 278 1000 (Orlando - ET)

+1 312 626 6799 (Chicago - CT)

+1 507 473 4847 (Minnesota - CT)

+1 346 248 7799 (Houston - CT)

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business

BOSTON, Mass – May 7, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.

First Quarter 2026 Financial Results

•As previously announced, Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026 and is presenting the financial results of operations for the former business within discontinued operations. Accordingly, Ginkgo’s previously reported financial results for comparable periods have been retrospectively recast to conform to this presentation and reflect Ginkgo as a single reporting segment.

•First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%. As previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities.

•First quarter 2026 GAAP net loss from continuing operations of $(76) million, compared to $(83) million in the comparable prior year period.

•First quarter 2026 Adjusted EBITDA of $(42) million, down from $(44) million in the comparable prior year period.

•Cash, cash equivalents and marketable securities balance as of March 31, 2026 of $373 million.

"We believe autonomous labs will replace the lab bench more quickly than people think," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "Nebula is already the world's largest autonomous lab with the ability to run real customer science around the clock and we're targeting to double its size this year. We see a large market that remains overwhelmingly manual today, and every experiment our Solutions, Datapoints, and Cloud Lab businesses run on Nebula generates revenue today while making the platform better for tomorrow. Ginkgo is singularly focused on leading the transition from the lab bench to autonomous research infrastructure that runs 24/7 and integrates directly with the AI models transforming drug discovery and industrial biotechnology."

Recent Business Highlights & Strategic Positioning

•We believe that autonomous labs will replace the bench.

◦The return on investment of the autonomous lab is clear for customers, with millions of square feet and tens of billions per year being spent on work happening at the lab bench

◦The autonomous lab is a machine that can run 24/7 and can be seamlessly integrated into emerging AI models

•Nebula, our autonomous lab, is showing what is possible at the bleeding edge.

◦Nebula is the world’s largest autonomous lab and in 2026 we are aiming to double its size

◦Recent coverage positions Ginkgo at the frontier of scientific innovation in the scientific (Nature), trade (R&D World), mainstream (Forbes, The Washington Post), and tech press (Sequoia’s Training Data, TBPN)

◦Policymakers and heads of R&D visit for our internal demonstrations. During SLAS 2026, over 500 visitors came to tour Nebula

•Cloud Lab, Datapoints, and Solutions are our version of Starlink.

◦They both create revenue and speed the development of the autonomous lab

◦We are seeing traction with our Cloud Lab from partners such as ProQR and Amazon, who included us as an integrated wet lab partner on their Amazon Bio Discovery platform

Full Year 2026 Outlook

•Ginkgo reaffirms expected total cash burn of $(150)-$(125) million in 2026.

Conference Call Details

Ginkgo will host a videoconference today, Thursday, May 7, beginning at 4:30 p.m. ET. The presentation will include an overview of the first quarter 2026, recent business updates, a discussion on Ginkgo’s outlook, as well as a moderated question and answer session.

To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to investors@ginkgobioworks.com.

A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.

Ginkgo Investor Website: https://investors.ginkgobioworks.com/events/

Audio-Only Dial Ins:

+1 646 876 9923 (New York - ET)

+1 301 715 8592 (Washington DC - ET)

+1 305 224 1968 (Miami - ET)

EX-99.1

2 ex991earningspr.htm

EX-99.1

Document

Exhibit 99.1

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

Ginkgo provides an update on its fourth quarter and full year financial results

BOSTON, Mass – February 26, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

Fourth Quarter 2025 Financial Results

•Fourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year period, Total revenue in the fourth quarter of 2025 decreased 24% from the comparable prior year period.

◦Fourth quarter 2025 Cell Engineering revenue of $26 million compared to $35 million in the comparable prior year period, a decrease of 26%

◦Fourth quarter 2025 Biosecurity revenue of $7 million compared to $9 million in the comparable prior year period

•Fourth quarter 2025 GAAP net loss of $(81) million, compared to $(108) million in the comparable prior year period

•Fourth quarter 2025 Adjusted EBITDA of $(36) million, up from $(57) million in the comparable prior year period, primarily attributable to the decrease in operating expenses in the prior year period

•Cash, cash equivalents and marketable securities balance as of December 31, 2025 of $423 million

“This year, we are going to focus on investing to win in the category of autonomous labs,” said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. “There is an emerging wave of interest in robotics and AI, and our work with the Department of Energy and OpenAI this year shows that Ginkgo is in the best position to bring robotics to an extraordinarily high value area: laboratory research.”

Full Year 2025 Financial Results

•Full year 2025 Total revenue of $170 million, down from $227 million in the prior year, a decrease of 25% driven by the shift from early stage customers to large/enterprise customers along with commercial changes related to the restructuring. Full year 2025 and 2024 also benefited from $8 million and $45 million of non-cash revenue from previously announced releases of deferred revenue relating to the mutual terminations of customer agreements.

◦Full year 2025 Cell Engineering revenue of $133 million, down from $174 million in the prior year, a decrease of 24%. Excluding the non-cash deferred revenue releases discussed above, full year 2025 and 2024 Cell Engineering revenue of $125 million and $129 million, respectively, with 2025 Cell Engineering revenue decreasing 3%, primarily attributed to ongoing program rationalization as part of our restructuring activities. Full year 2025 Biosecurity revenue of $37 million, down from $53 million in the prior year, a decrease of 30%, with full year 2025 Biosecurity gross profit margin of 23%

•Full year 2025 GAAP net loss of $(313) million, compared to $(547) million in the prior year

•Full year 2025 Adjusted EBITDA of $(167) million, improved from $(293) million in the prior year

Biosecurity Business Divestiture

Ginkgo today announced it has reached an agreement to sell the Company’s biosecurity business to a consortium of investors (“Investors”) in exchange for a minority equity position in the business alongside the Investors. Upon completion, the biosecurity business will operate as a standalone private entity focused on building a scaled, biosecurity infrastructure

platform for the United States and its global partners. The transaction provides the biosecurity business with greater flexibility and additional resources to pursue near- and long-term growth opportunities.

Per Ginkgo CEO Jason Kelly, “There is rising interest in defense tech in private capital markets and spinning off our biosecurity business into a private entity with new investors allows it to grow faster with more investment than it would inside Ginkgo. This serves Ginkgo in two ways: we are able to participate in the upside of the new entity as a shareholder but importantly we also focus Ginkgo’s cash investment on our autonomous labs business.”

Ginkgo expects to complete the transaction in the first half of 2026, subject to the satisfaction of customary closing

conditions.

Recent Business Highlights & Strategic Positioning

•We are making 2026 a year of investment in our autonomous lab.

◦This year, we will focus Ginkgo's efforts on autonomous labs as the common platform for biotechnology research and invest to extend our current lead in technology. We are currently expanding our frontier autonomous lab in Boston to include over 50 RACs, with 50 more expected by the end of the year

◦We will demonstrate the capabilities of autonomous labs by decommissioning the majority of Ginkgo's